The latest data on childhood immunisation coverage by Primary Health Network (PHN) is now available for the period 1 April 2020 – 31 March 2021.
In Central and Eastern Sydney PHN, coverage rates have improved for the 1 year old and 2 year old cohorts. See data for all children March 2021 annualised data and data for children in our region CESPHN coverage rates. COVID-19 Vaccine Rollout Update
National Cabinet agreed to a recalibrated model of the COVID-19 Vaccination Rollout Strategy to account for the updated ATAGI advice, that Pfizer be the preferred vaccine for people under 50.
This model includes bringing forward access for eligible individuals aged 50 to 69.
From 3 May 2021: people 50 years and over can receive the AstraZeneca vaccine at General Practice Respiratory Clinics and state and territory vaccination clinics.
From 17 May 2021: people 50 years and over can receive the AstraZeneca vaccine at a participating general practice.
General practices can apply to the Australian Government Department of Health to begin vaccinating the over 50’s population earlier through their PHN by emailing email@example.com
After this date Zostavax will only be funded for people 70 years of age, and people aged 71 years and over will be required to purchase the vaccine privately.
Who should be vaccinated?
Identify and contact eligible patients aged 71 to 79 years using your data extraction tools PenCAT or POLAR. For assistance, contact your digital health officer at firstname.lastname@example.org
Who should not be vaccinated?
People who are immunocompromised due to disease or medication, pregnant women, and those who have previously had anaphylaxis to any VZV-containing vaccine or its components should not receive the zoster vaccine.
AusVaxSafety has monitored the safety of influenza vaccines administered to Australians of all ages since 2017. Since then, over 477,000 individuals or their parent/carer have provided details about any adverse events experienced after influenza vaccination.
Parent-friendly influenza vaccination resources from SKAI
Influenza vaccination resources for parents are available from Sharing Knowledge About Immunisation (SKAI). Written specifically for parents, the resources are designed to support their influenza vaccination information needs and guide them in their decision to vaccinate.
Administration & Timing of COVID-19 and other vaccines
Routine co-administration of a COVID-19 vaccine on the same day as another vaccine is not recommended:
There should be a minimum interval of 14 days between receipt of a COVID-19 vaccine and any other vaccine, whether live or non-live.
If a COVID-19 vaccine has inadvertently been administered on the same day or within 14 days before or after other vaccines, no vaccine doses need to be repeated.
Although immune interference is unlikely between vaccines that do not contain common antigens, there are currently no immunogenicity or safety data on co-administration of COVID-19 vaccines with other vaccines.
Shortening of the interval between COVID-19 vaccine and another vaccine:
An individual risk–benefit assessment is necessary to consider shortening of the interval between, or offer same day administration of, a COVID-19 vaccine with another vaccine.
This may be considered if there is a high risk of imminent exposure to the vaccine-targeted disease, or it is highly likely that the opportunity of receiving either vaccine will be missed.
If same day or reduced-interval vaccination is proposed, patients should be counselled about the possible adverse events from each vaccine and advised to report adverse events.
The recommended interval between two doses of COVID-19 Vaccine AstraZeneca is 12 weeks.
Shortening the interval from 12 weeks (to no less than 4 weeks) between doses is acceptable and may be appropriate in certain circumstances such as imminent travel, anticipated risk of COVID-19 exposure, etc.
The minimum interval and recommended interval between doses:
If a dose has been inadvertently given before the minimum 4-week interval, it is not currently recommended that the vaccine dose be repeated.
If the second dose of COVID-19 Vaccine AstraZeneca is administered later than the recommended 12-week interval, no vaccine doses need to be repeated.
On the basis of currently available information, Comirnaty and COVID-19 Vaccine AstraZeneca are not considered interchangeable:
The two-dose course should be completed with the same vaccine.
There are no data yet on the efficacy of mixed schedules.
If an individual develops anaphylaxis or a severe allergic reaction after the first dose of a COVID-19 vaccine, an alternate brand can be considered for the second dose. If an alternate brand is used for the second dose, a third dose of COVID-19 vaccine does not need to be given.
COVID-19 vaccine updates for GPs
Join the latest COVID-19 vaccine live stream update for GPs.
The panel will provide latest key updates and answer participants’ questions live about the COVID-19 vaccine rollout.
This webinar discusses updates on the Australian Government COVID-19 vaccine roll out plan and what this means for immunisation providers, information on thrombosis with thrombocytopenia syndrome (TTS) and AstraZeneca COVID-19 Vaccine, and practical strategies for communicating with your patients to increase vaccine acceptance and uptake.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…